News Lilly and Boehringer biosimilar undercuts Lantus by 15% Sanofi under pressure following long-awaited biosimilar launch.
News "I'm going to bring down drug prices" - Trump President-elect takes swipe at pharma after Time "Person of the Year" accolade.
News Cost the barrier, but Novo not giving up on insulin pill, sa... Cost of pill will be too much for payers to stomach, says Novo.
Views & Analysis The 'game changers' in diabetes: Novo and Lilly battle it ou... Two diabetes drugs, Lilly and Boehringer Ingelheim’s (BI) Jardiance and Novo Nordisk’s Victoza, have shown they can go beyond lowering blood sugar, and actually save lives and cut heart attacks
News Novo's next-gen diabetes drug could be best at cutting heart... Novo boosted by results from next-gen GLP-1.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
